CyGen Advisors Honored with Major Awards at the 2026 SNMMI Annual Meeting

by | Jun 1, 2026 | News

CyGen Alpha Systems is proud to recognize two members of its Advisory Board who were honored at the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, one of the world’s leading conferences for nuclear medicine, molecular imaging, and radiopharmaceutical science.

Dr. Peter J. H. Scott Receives the 2026 Michael J. Welch, PhD Award

CyGen Advisor Dr. Peter J. H. Scott was awarded the prestigious 2026 Michael J. Welch, PhD Award, which recognizes individuals who have made outstanding contributions to radiopharmaceutical sciences, mentorship, and advancement of the nuclear medicine community.

Dr. Scott serves as Chief of Nuclear Medicine and Director of the PET Center at the University of Michigan and is internationally recognized for his work in radiochemistry, PET imaging, and isotope production technologies.

(Read more about the Michael J. Welch PhD Award by clicking here)

Award recognition graphic honoring CyGen advisors Dr. Peter J. H. Scott and Dr. Tadashi Watabe at the 2026 SNMMI Annual Meeting

Dr. Tadashi Watabe Earns JNM Editors’ Choice Honors

CyGen Advisor Dr. Tadashi Watabe received both the Best Clinical Article Award and the Overall Best Article Award from the Journal of Nuclear Medicine for his groundbreaking publication:

“First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial).”

The study represents one of the first human clinical investigations of Astatine-211 (At-211) targeted alpha therapy and highlights the growing momentum behind next-generation alpha-emitting radiopharmaceuticals.

(Read more about the Choice Honors by clicking here)

Concept rendering of a modern radiopharmaceutical production facility designed to support medical isotope manufacturing and precision oncology infrastructure.

Advancing the Future of Radiopharmaceutical Infrastructure

The recognition of both Dr. Scott and Dr. Watabe underscores the caliber of scientific and clinical expertise supporting CyGen’s mission to expand domestic radiopharmaceutical production infrastructure.

As targeted alpha therapies continue to advance from research into clinical practice, CyGen remains focused on helping address the critical isotope supply bottleneck through the development of advanced GMP-compliant production facilities designed to support the next generation of cancer imaging and treatment.

CyGen congratulates Dr. Scott and Dr. Watabe on these significant achievements and their continued contributions to the advancement of nuclear medicine and precision oncology.

Register for the Next CyGen Investor Webinar
Learn how medical isotope infrastructure is helping address one of cancer care’s critical supply bottlenecks.
View Webinar Times